In this study of healthy women, participants were randomized to receive a placebo or MBP at 40 mg per day for six months. A significant increase in BMD and a decrease in bone metabolism and bone loss was observed in the MBP group, compared to the placebo group. The authors conclude that the increase in BMD might be mediated primarily through the inhibition of osteoclast –mediated bone resorption by MBP.
Aoe, S., Toba, Y., Yamamura, J., Kawakami, H., Yahiro, M., Kumegawa, M., Itabashi, A., & Takada, Y. (2001). Bioscience, biotechnology, and biochemistry, 65(4), 913–918. https://doi.org/10.1271/bbb.65.913